Cargando…

Arylimidamides Have Potential for Chemoprophylaxis against Blood-Transmitted Chagas Disease

Chagas disease (CD) affects over 6 million people worldwide and can be transmitted iatrogenically. Crystal violet (CV) was previously used for pathogen reduction but has harmful side-effects. In the present study, three arylimidamides (AIAs) and CV were used to sterilize mice blood samples experimen...

Descripción completa

Detalles Bibliográficos
Autores principales: Timm, Bruno Lisboa, da Gama, Aline Nefertiti Silva, Batista, Marcos Meuser, Batista, Denise da Gama Jaén, Boykin, David W., De Koning, Harry P., Correia Soeiro, Maria de Nazaré
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10224031/
https://www.ncbi.nlm.nih.gov/pubmed/37242371
http://dx.doi.org/10.3390/pathogens12050701
Descripción
Sumario:Chagas disease (CD) affects over 6 million people worldwide and can be transmitted iatrogenically. Crystal violet (CV) was previously used for pathogen reduction but has harmful side-effects. In the present study, three arylimidamides (AIAs) and CV were used to sterilize mice blood samples experimentally contaminated with bloodstream trypomastigotes (BT) of Trypanosoma cruzi, at non hemolytic doses. All AIAs were not toxic to mouse blood cells until the highest tested concentration (96 µM). The previous treatment of BT with the AIAs impaired the infection establishment of cardiac cell cultures. In vivo assays showed that pre-incubation of mouse blood samples with the AIAs and CV (96 µM) significantly suppressed the parasitemia peak, but only the AIA DB1831 gave ≥90% animal survival, while vehicle treated samples reached 0%. Our findings support further studies regarding the potential use of AIAs for blood bank purposes.